Stefania Chiappini, Rachel Vickers-Smith, Daniel Harris, G Duccio Papanti Pelletier, John Martin Corkery, Amira Guirguis, Giovanni Martinotti, Stefano L Sensi, Fabrizio Schifano
Recent media reports commented about a possible issue of the misuse of antidiabetics related to molecules promoted as a weight-loss treatment in non-obese people. We evaluated here available pharmacovigilance misuse/abuse signals related to semaglutide , a glucagon-like peptide-1 (GLP-1) analogue, in comparison to other GLP-1 receptor agonists ( albiglutide , dulaglutide , exenatide , liraglutide , lixisenatide , and tirzepatide ) and the phentermine - topiramate combination. To acheieve that aim, we analyzed the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) dataset, performing a descriptive analysis of adverse event reports (AERs) and calculating related pharmacovigilance measures, including the reporting odds ratio (ROR) and the proportional reporting ratio (PRR)...
July 11, 2023: Pharmaceuticals